<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="336492">
  <stage>Registered</stage>
  <submitdate>9/02/2011</submitdate>
  <approvaldate>9/02/2011</approvaldate>
  <actrnumber>ACTRN12611000156987</actrnumber>
  <trial_identification>
    <studytitle>Myocardial tissue characterisation in left ventricular hypertrophy using echocardiography and cardiac magnetic resonance.</studytitle>
    <scientifictitle>Myocardial tissue characterisation in left ventricular hypertrophy using echocardiography and cardiac magnetic resonance.</scientifictitle>
    <utrn>U1111-1119-2838</utrn>
    <trialacronym />
    <secondaryid>None</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Aortic Stenosis</healthcondition>
    <healthcondition>Systemic Hypertension</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular</conditioncode1>
      <conditioncode2>Hypertension</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cardiovascular</conditioncode1>
      <conditioncode2>Other cardiovascular diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Echocardiogram will be performed to measure strain and diastolic cardiac function. Cardiac Magnetic Resonance Imaging will be performed to measure myocardial fibrosis and perfusion reserve .  These tests will take approximately 90 minutes, and will performed once only in each patient, from either the aortic stenosis cohort, the systemic hypertension cohort or the healthy subjects.</interventions>
    <comparator>Nil</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Not applicable</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To determine whether the differences seen in LV hypertrophy in aortic stenosis by echocardiography and Cardiac MRI parameters of complex heart motion and tissue characterisation differentiate it from other forms of pathological hypertrophy.</outcome>
      <timepoint>Echocardiography and Cardiac MRI on enrollment.</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>To determine whether the differences seen in left ventricular hypertrophy in systemic hypertension by echocardiography and Cardiac MRI parameters of complex heart motion and tissue characterisation differentiate it from other forms of pathological hypertrophy.</outcome>
      <timepoint>Echocardiography and Cardiac MRI on enrollment.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>None</outcome>
      <timepoint>Nil</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Cohort 1. Patients with history of aortic stenosis. 
Cohort 2. patients with history of systemic hypertension
Cohort 3. healthy subjects, no history of AS or hypertension</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Known cardiovascular disease 
Known peripheral vascular disease
Hypercholesterolemia (total cholesterol &gt; 6mmol/L)
Diabetes (type I or II) 
Metabolic syndrome and a BMI of &lt; 30
Standard MRI contraindications, including permanent pacemaker, implantable defibrillator, severe claustrophobia. 
Renal impairment (eGFR &lt; 60ml/min) will be an exclusion criterion from the administration of gadolinium</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs>Screening</purposeobs>
    <duration>Cross-sectional</duration>
    <selection>Defined population</selection>
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>28/02/2011</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>75</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Professor Joesph Selvanayagam</primarysponsorname>
    <primarysponsoraddress>Department Cardiovascular Medicine
Flinders Medical Centre
1 Flinders Drive
BEDFORD PARK
SA 5042</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>Flinders Medical Centre</fundingname>
      <fundingaddress>Flinders Medical Centre
1 Flinders Drive
BEDFORD PARK
SA 5042</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This research project composes of collecting echocardiographic and cardiac MRI (CMR) data on two populations of patients; those with severe aortic stenosis and those with systemic hypertension and comparing them to healthy subjects.  We would like to use the data collected on these two cohorts of patients to look at 2 dimensional strain imaging, tissue Doppler imaging, three dimensional volumes and myocardial fibrosis.  By using these advanced imaging techniques we can evaluate and quantify left ventricular (LV) hypertrophy and myocardial characteristics.  This may give us a better understanding of cardiac remodelling and the function of the heart muscle in each of these disease states.  We hypothesise that differences in myocardial function and tissue characterisation detected by these imaging techniques may be detected in patients aortic stenosis and hypertension with similar degrees of LV hypertrophy.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>The Southern Adelaide Health Service / Flinders University Human Research Ethics Committee</ethicname>
      <ethicaddress>Human Research Ethics
Southern Adelaide Health Service
SA Health 
Room 2A221 - Inside Human Resources
Flinders Medical Centre
1 Flinders Drive
Bedford Park SA 5042</ethicaddress>
      <ethicapprovaldate>28/01/2011</ethicapprovaldate>
      <hrec>22/11/2011</hrec>
      <ethicsubmitdate>18/01/2011</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Amy Penhall</name>
      <address>Department Cardiovascular Investigations
Flinders Medical Centre
1 Flinders Drive
BEDFORD PARK
SA 5042</address>
      <phone>+61 8 8404 2004</phone>
      <fax />
      <email>amy.penhall@health.sa.gov.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Kate Schwartz</name>
      <address>Flinders Clinical Research
Level 3A
Mark Oliphant Building
Laffer Drive
BEDFORD PARK
SA 5042</address>
      <phone>+61 8 8201 7700</phone>
      <fax>+61 8 8201 7701</fax>
      <email>kate.schwartz@health.sa.gov.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Kate Schwartz</name>
      <address>Flinders Clinical Research
Level 3A
Mark Oliphant Building
Laffer Drive
BEDFORD PARK
SA 5042</address>
      <phone>+61 8 8201 7700</phone>
      <fax>+61 8 8201 7701</fax>
      <email>kate.schwartz@health.sa.gov.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>